


Arrepath's lead inhibitors are highly potent against Enterobacterales, disrupting enzyme activity and killing the bacteria, without killing human cells



With funding and support from PACE, Arrepath will



Advancing small-molecule drug leads to inhibit a crucial enzyme in 'Enterobacterales' bacteria

Arrepath's novel AI/machine learning platform can test millions of different compounds for antibacterial activity

• Optimise inhibitor properties

• Demonstrate effectiveness against E.coli and additional **Enterobacterales species**

Success will enable Arrepath to advance the development of new antibiotics for treating the most severe bacterial infections in both intravenous and oral pill formats, to support patients' needs



